Accéder au contenu
Merck
Toutes les photos(1)

Documents

SML2287

Sigma-Aldrich

Posaconazole

≥98% (HPLC)

Synonyme(s) :

Posaconazole solution, 2,5-Anhydro-1,3,4-trideoxy-2-C-(2,4-difluorophenyl)-4-[[4-[4-[4-[1-[(1S,2S)-1-ethyl-2-hydroxypropyl]-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl]phenyl]-1-piperazinyl]phenoxy]methyl]-1-(1H-1,2,4-triazol-1-yl)-D-threo-pentitol, Sch 56592

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C37H42F2N8O4
Numéro CAS:
171228-49-2
Poids moléculaire :
700.78
Numéro MDL:
MFCD00941162
Code UNSPSC :
12352200
Nomenclature NACRES :
NA.77

Pureté

≥98% (HPLC)

Forme

powder

Activité optique

[α]/D -24 to -32°, c = 1.0 in chloroform-d

Couleur

white to beige

Solubilité

DMSO: 2 mg/mL, clear

Température de stockage

−20°C

InChI

1S/C37H42F2N8O4/c1-3-35(26(2)48)47-36(49)46(25-42-47)31-7-5-29(6-8-31)43-14-16-44(17-15-43)30-9-11-32(12-10-30)50-20-27-19-37(51-21-27,22-45-24-40-23-41-45)33-13-4-28(38)18-34(33)39/h4-13,18,23-27,35,48H,3,14-17,19-22H2,1-2H3/t26-,27+,35-,37-/m0/s1

Clé InChI

RAGOYPUPXAKGKH-XAKZXMRKSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Application

Posaconazole has been used:
  • in antifungal susceptibility testing of Aspergillus terreus
  • as a lanosterol 14α-demethylase (CYP51)-specific inhibitor to study its effects on membrane permeability in Candida albicans cells
  • to study its effects on promastigotes

Actions biochimiques/physiologiques

Posaconazole is a highly potent broadspectrum antifungal agent against the yeast infection caused especially by Candida sp. It blocks the growth of fungi by inhibiting the enzyme lanosterol 14α-demethylase (CYP51). In contrast to other antifungal azoles, posaconazole has been reported not to induce the efflux pump mechanism. Posaconazole exhibits antichagasic effects against different strains of Trypanosoma cruzi causing Chagas disease.

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 10

1 of 10

Voriconazole VETRANAL®, analytical standard

Supelco

32483

Voriconazole

Itraconazole Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1834

Itraconazole

Fluconazole ≥98% (HPLC), powder

Sigma-Aldrich

F8929

Fluconazole

Posaconazole-D4 solution 1.0 mg/mL in methanol, certified reference material, Cerilliant®

Supelco

P-108

Posaconazole-D4 solution

Voriconazole European Pharmacopoeia (EP) Reference Standard

Y0001395

Voriconazole

Fexinidazole ≥98% (HPLC)

Sigma-Aldrich

SML2524

Fexinidazole

Itraconazole European Pharmacopoeia (EP) Reference Standard

I7000000

Itraconazole

mTOR Inhibitor XI, Torin1 mTOR Inhibitor XI, Torin1, CAS 1222998-36-8, is a cell-permeable, highly potent, ATP-competitive inhibitor of mTOR and DNA-PK (IC50 = 4.32 and 6.34 nM, respectively).

Sigma-Aldrich

475991

mTOR Inhibitor XI, Torin1

U 18666A powder

Sigma-Aldrich

U3633

U 18666A

Ketoconazole 99.0-101.0% (EP, titration)

Sigma-Aldrich

K1003

Ketoconazole

Harrys A Torres et al.
The Lancet. Infectious diseases, 5(12), 775-785 (2005-11-29)
Posaconazale is a new triazole drug being investigated in phase III clinical trials for the treatment and prevention of invasive fungal infections. In-vitro and in-vivo studies showed that posaconazole has broad-spectrum activity against most Candida species, Cryptococcus neoformans, Aspergillus species
Yanjun Li et al.
Clinical pharmacokinetics, 49(6), 379-396 (2010-05-21)
Posaconazole is a recently approved lipophilic triazole antifungal agent that exhibits potent and broad-spectrum antifungal activity in vitro and in vivo against most Candida spp., Cryptococcus neoformans, Aspergillus spp., many Zygomycetes, endemic fungi and dermatophytes. It has been documented that
Chiung-Kuang Chen et al.
PLoS neglected tropical diseases, 4(4), e651-e651 (2010-04-14)
Chagas Disease is the leading cause of heart failure in Latin America. Current drug therapy is limited by issues of both efficacy and severe side effects. Trypansoma cruzi, the protozoan agent of Chagas Disease, is closely related to two other
Israel Molina et al.
Current opinion in infectious diseases, 28(5), 397-407 (2015-07-24)
The current therapeutic scenario against Chagas disease has been recently updated with the use of the triazoles in clinical trials and several experimental assays (in-vitro and in-vivo models) which are bringing novel and promising evidence for the treatment of Chagas
Galina I Lepesheva et al.
The Journal of biological chemistry, 285(33), 25582-25590 (2010-06-10)
Trypanosoma cruzi causes Chagas disease (American trypanosomiasis), which threatens the lives of millions of people and remains incurable in its chronic stage. The antifungal drug posaconazole that blocks sterol biosynthesis in the parasite is the only compound entering clinical trials
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique